Clinical trials: sponsored by BeOne Medicines
Healthy Volunteers
A Study to Investigate the Relative Bioavailability and Food Effect of Tablet for Oral Suspension of Sonrotoclax in Healthy Adults
The purpose of this study is to evaluate whether blood levels of sonrotoclax after administration of a tablet for oral suspension are similar to those observed with the current sonrotoclax tablet.
- Trial name
- NCT07628881
- Testing
- Sonrotoclax Tablet for Oral Suspension, Sonrotoclax Tablet
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Healthy Adult Participants
A Trial in Healthy Participants to Assess Drug Interaction Potential of BGB-43395
This study will enroll healthy participants to evaluate whether BGB-43395 interacts with other drugs, including midazolam, celecoxib, dabigatran, and rosuvastatin.
- Trial name
- NCT07820891
- Testing
- BGB-43395, Midazolam, Celecoxib
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Hepatic Impairment, Healthy Adult Participants
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Sonrotoclax in Participants With Severe Hepatic Impairment
The goal of this study is to understand how the body processes sonrotoclax in adults with serious liver problems compared to adults with normal liver function.
- Trial name
- NCT07855991
- Testing
- Sonrotoclax
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Healthy Volunteers
A Study to Investigate the Effect of the CYP3A Inducer Phenytoin and the CYP3A Inhibitor Itraconazole on the Pharmacokinetics of BGB-58067 in Healthy Participants
This study is being done to understand how the body processes the study drug (BGB-58067) when it is taken together with other medicines. BGB-58067 is mainly broken down in the body by a liver enzyme called CYP3A.
- Trial name
- NCT07590102
- Testing
- BGB-58067, Phenytoin, Itraconazole
- Where
- Australia
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Hepatic Impairment, Healthy Adult Participants
A Study to Investigate Safety, Tolerability, and Pharmacokinetics of Tacabrutideg (BGB-16673) in Participants With Moderate and Severe Hepatic Impairment
The goal of this study is to understand how the body processes tacabrutideg in adults with different levels of liver function (normal, moderate impairment, and severe impairment).
- Trial name
- NCT07856004
- Testing
- Tacabrutideg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Healthy Volunteers
A Study to Investigate the Relative Bioavailability of 2 Tablet Formulations and the Effect of Food on the Pharmacokinetics of BGB-58067 in Healthy Participants
This study is being done to understand how the body processes 2 different tablet formulations of the study drug (BGB-58067) and how food intake influences the processing of the study drug by the body.
- Trial name
- NCT07712640
- Testing
- BGB-58067 Tablet (F-01 Formulation), BGB-58067 Tablet (F-02 Formulation)
- Where
- Australia
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
This is a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of tacabrutideg in adults with chronic spontaneous urticaria (CSU) and in healthy participants.
- Trial name
- NCT07005713
- Testing
- Tacabrutideg
- Where
- 9 sites in China
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Skin Diseases
A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases
This is the first-in-human study of BG-A3004. The study will evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics (PD) of BG-A3004 after single and multiple doses administered in…
- Trial name
- NCT07412691
- Testing
- BG-A3004
- Where
- 11 sites in China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Healthy Volunteers
A Study to Investigate the Relative Bioavailability and Food Effect of a Fixed-Dose Combination Tablet Containing Zanubrutinib and Sonrotoclax (BG-71332) in Healthy Adults
The purpose of this study is to evaluate the relative bioavailability of a fixed-dose combination tablet containing zanubrutinib and sonrotoclax (BG-71332) compared to a zanubrutinib capsule and sonrotoclax tablet administered…
- Trial name
- NCT07141511
- Testing
- BG-71332, Zanubrutinib, Sonrotoclax
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines